What is Licochalcone A and where does it come from?

Licochalcone A (LA) is a retrochalcone flavonoid (C21H22O4, CAS 58749-22-7) isolated from the roots and rhizomes of Glycyrrhiza inflata, a species of Chinese licorice grown in arid regions of northwestern China and Central Asia. It is a species-specific phytochemical that distinguishes G. inflata from other Glycyrrhiza species and is extracted from the plant's underground storage organs via standard phytochemical or metabolic engineering methods. LA is a modern research isolate rather than a traditionally used standalone compound.

What cancers has Licochalcone A been studied against?

Preclinical research has tested LA against a broad range of cancer cell lines, including MCF-7 and MDA-MB-231 (breast cancer), A549 and H460 (non-small cell lung cancer), HepG2 (hepatocellular carcinoma), U87 (glioblastoma), HT-1080 (fibrosarcoma, IC50 5.176 μM), and nasopharyngeal carcinoma cells. LA induces apoptosis and cell cycle arrest in these models at concentrations of 2–125 μM depending on the cell type and endpoint measured. All data are from laboratory cell culture and rodent experiments; no human cancer clinical trials have been conducted.

How does Licochalcone A kill cancer cells?

LA activates the intrinsic (mitochondrial) apoptosis pathway by elevating intracellular reactive oxygen species, reducing mitochondrial membrane potential, and triggering caspase-3, -8, and -9 activation alongside PARP cleavage, while upregulating pro-apoptotic Bax and downregulating survival protein Bcl-2. Simultaneously, it suppresses key oncogenic signaling pathways including PI3K/AKT/mTOR, NF-κB, MAPK (JNK/p38/ERK), and transcription factor Sp1, and induces G2/M cell cycle arrest via Wee1/p21 upregulation and Cyclin B1/CDK1 downregulation. These mechanisms collectively prevent cancer cell proliferation, survival, invasion, and migration across multiple tumor types in preclinical models.

Is Licochalcone A safe to take as a supplement?

Licochalcone A is not currently available as a standardized dietary supplement, and no human safety data, clinical toxicology studies, or established safe doses exist for this compound in people. Preclinical studies show that 25 μM is non-toxic in human stem cells and doses up to 80 mg/kg in rodents appear well-tolerated, but these findings cannot be directly translated to human supplementation recommendations. Until Phase I clinical trials establish human pharmacokinetics and a safety profile, LA should not be self-administered as an isolated compound.

Does Licochalcone A have anti-HIV activity?

Preclinical evidence indicates that Licochalcone A can inhibit the formation of HIV-induced syncytia (multinucleated giant cells), which are a pathological feature of HIV infection caused by viral-mediated cell-to-cell fusion. This anti-HIV activity represents growth inhibition of the giant cell formation process rather than direct virucidal action, and the precise molecular target within the HIV replication or fusion mechanism has not been fully characterized. No human clinical studies evaluating LA against HIV infection have been conducted, so these findings remain hypothesis-generating laboratory observations only.

What is the bioavailability of Licochalcone A, and does the form of Glycyrrhiza inflata extract matter?

Licochalcone A bioavailability depends on the extraction method and formulation used; standardized extracts typically achieve higher circulating levels than whole plant material. Studies showing cytotoxic effects in cancer cells use concentrations ranging from 5–80 μM, but human bioavailability data remains limited, making it difficult to predict equivalent supplement doses. Lipophilic formulations or delivery systems may enhance absorption compared to standard aqueous extracts.

Does Licochalcone A interact with common cancer medications or chemotherapy drugs?

Limited clinical data exists on drug interactions between Licochalcone A and chemotherapy agents, though in-vitro studies suggest it induces similar apoptotic pathways (Bax upregulation, Bcl-2 downregulation) to conventional anticancer drugs. Concurrent use with chemotherapy should be discussed with an oncologist, as potential synergistic or antagonistic effects have not been adequately evaluated in human trials. Current evidence does not permit safe recommendations for combining LA supplements with active cancer treatment.

Who should avoid Licochalcone A supplementation, and what populations need additional caution?

Pregnant and breastfeeding women should avoid Licochalcone A due to lack of safety data and its demonstrated pro-apoptotic effects on human cells. Individuals with estrogen-sensitive cancers (breast, ovarian) should consult healthcare providers before use, as some in-vitro data suggests estrogenic activity in certain cell models. People taking immunosuppressants or with bleeding disorders should exercise caution, as licorice compounds may modulate immune function and platelet aggregation.

Licochalcone A

Licochalcone A (C21H22O4) is a retrochalcone flavonoid that induces cancer cell apoptosis and cycle arrest by activating intrinsic mitochondrial pathways, elevating reactive oxygen species, and suppressing oncogenic signaling cascades including PI3K/AKT/mTOR, NF-κB, and MAPK. In preclinical models, LA demonstrates potent cytotoxicity across multiple cancer cell lines, with an IC50 of 5.176 μM in HT-1080 fibrosarcoma cells and apoptosis induction at 5–15 μM in MCF-7 breast cancer cells, alongside anti-HIV activity evidenced by inhibition of HIV-induced giant cell formation.

Category: Compound Evidence: 1/10 Tier: Preliminary

Origin & History

Licochalcone A (LA) is a retrochalcone flavonoid isolated primarily from the roots and rhizomes of Glycyrrhiza inflata (Chinese licorice), a perennial herb native to arid and semi-arid regions of northwestern China, Central Asia, and the Middle East. The compound accumulates preferentially in the underground storage organs of G. inflata, distinguishing this species from other Glycyrrhiza species such as G. glabra or G. uralensis, which contain different predominant chalcones. Commercial extraction relies on cultivated or wild-harvested G. inflata roots, with metabolic engineering approaches under investigation to improve biosynthetic yield of this specific secondary metabolite.

Historical & Cultural Context

Licochalcone A is derived from the roots of Glycyrrhiza inflata, a species whose roots have been used in Traditional Chinese Medicine (TCM) for over 4,000 years under the name 'Gan Cao' (甘草), primarily for its anti-inflammatory, detoxifying, and harmonizing properties in multi-herb formulations. However, LA itself is a modern chemical isolate first characterized and named in the late 20th century; traditional TCM practitioners worked with whole root extracts containing the full spectrum of licorice phytochemicals, not isolated chalcones. The biological differentiation of G. inflata from G. glabra and G. uralensis—the licorice species more commonly used in Western herbal medicine and European pharmacopeias—was established largely through phytochemical investigation revealing LA as a species-specific chemotaxonomic marker. Modern pharmacognostic interest in LA emerged from systematic screening of licorice-derived compounds for bioactivity in the context of cancer and infectious disease drug discovery programs in the 1990s and 2000s.

Health Benefits

- **Anticancer Cytotoxicity**: LA induces apoptosis in diverse cancer cell lines (breast MCF-7, lung A549/H460, liver HepG2, sarcoma HT-1080) by upregulating pro-apoptotic Bax and PARP cleavage while downregulating anti-apoptotic Bcl-2 and Cyclin D1, achieving IC50 values as low as 5.176 μM in fibrosarcoma models.
- **Cell Cycle Arrest**: At concentrations of 20–80 μM, LA arrests nasopharyngeal carcinoma and other cancer cells at G2/M phase by upregulating Wee1 and p21 checkpoint proteins while downregulating Cyclin B1 and CDK1, effectively halting tumor cell proliferation.
- **Anti-Inflammatory Activity**: LA suppresses NF-κB signaling and pro-inflammatory cytokine production at 4–9 μM in murine mammary cell models and attenuates acute lung injury in mice at oral doses of 20–80 mg/kg, reducing inflammatory tissue damage.
- **Anti-HIV Activity**: LA inhibits the formation of HIV-induced syncytia (giant cells), a hallmark of viral pathogenesis, suggesting interference with HIV-mediated cell-to-cell fusion mechanisms, though the precise molecular target within the viral replication cycle requires further characterization.
- **Antifungal and Antibiofilm Effects**: At subinhibitory concentrations, LA reduces Candida albicans biofilm formation by 35–60% and suppresses Staphylococcus aureus alpha-toxin secretion, indicating dual antibacterial and antifungal utility relevant to combating resistant infections.
- **Antioxidant and Anti-Aging Properties**: LA at 25 μM enhances viability of human adipose-derived stem cells (hADSCs) without cytotoxicity by activating glycolytic pathways and reducing oxidative stress, suggesting a cytoprotective role in stem cell maintenance and tissue regeneration.
- **Anti-Invasion and Anti-Metastasis**: LA suppresses epithelial-to-mesenchymal transition (EMT) in MDA-MB-231 triple-negative breast cancer cells at 5–40 μM by modulating E-cadherin and vimentin expression through PI3K/AKT/Sp1 pathway inhibition, reducing migratory and invasive potential.

How It Works

Licochalcone A exerts its primary anticancer effects by engaging the intrinsic apoptotic pathway: it elevates intracellular reactive oxygen species (ROS), reduces mitochondrial membrane potential and ATP production, triggers cytochrome c release, and sequentially activates caspases-3, -8, and -9, ultimately cleaving PARP and committing cells to apoptotic death. LA simultaneously suppresses multiple oncogenic survival signaling axes—including PI3K/AKT/mTOR, JNK/p38/ERK (MAPK), NF-κB, and transcription factor Sp1—thereby blocking cancer cell proliferation, invasion, migration, and angiogenesis across diverse tumor types at micromolar concentrations (2–80 μM depending on model). The compound also induces autophagy via LC3-II accumulation downstream of PI3K/Akt/mTOR suppression and modulates post-transcriptional gene regulation through non-coding RNA pathways, adding a further layer of tumor-suppressive activity. In non-malignant contexts, LA activates glycolytic metabolism in stem cells and modulates oxidative stress responses, demonstrating target-context-dependent mechanistic versatility consistent with the pleiotropic bioactivity characteristic of polyphenolic chalcones.

Scientific Research

The entirety of available evidence for Licochalcone A derives from preclinical research comprising in vitro cell culture studies and rodent in vivo models; no human clinical trials have been conducted or reported as of the current literature review. In vitro studies have employed well-characterized cancer cell lines including MCF-7 (breast), MDA-MB-231 (triple-negative breast), A549 and H460 (lung), HepG2 (hepatocellular), U87 (glioblastoma), HT-1080 (fibrosarcoma), and nasopharyngeal carcinoma lines, with IC50 and effective concentration data spanning 2–125 μM across models. In vivo rodent studies have used doses of 20–80 mg/kg to demonstrate anti-inflammatory efficacy in acute lung injury models, and metabolic effects in adipose-derived stem cell transplantation paradigms. While the breadth of preclinical cancer models is notable and mechanistic characterization is reasonably detailed, the complete absence of human pharmacokinetic, toxicokinetic, or efficacy data represents a critical evidence gap that precludes any clinical translation conclusions at this time.

Clinical Summary

No clinical trials evaluating Licochalcone A in human subjects have been identified in the published literature or registered trial databases. All efficacy data originate from preclinical cell-based assays and small-animal experiments, which, while hypothesis-generating, do not establish human therapeutic doses, pharmacokinetics, bioavailability, or clinical outcomes. The compound has not been assessed in Phase I, II, or III trials for any indication, including cancer, HIV, or inflammatory disease. Confidence in clinical applicability is therefore very low, and LA should be regarded strictly as a research-stage molecule pending human pharmacological evaluation.

Nutritional Profile

Licochalcone A (LA) is a pure bioactive chalcone compound isolated from Glycyrrhiza inflata (Chinese licorice root), not a macronutrient source. It is not a significant provider of calories, protein, fiber, vitamins, or minerals. As a secondary plant metabolite, LA is present in Glycyrrhiza inflata root at concentrations estimated at 0.05–0.3% dry weight, substantially higher than in other licorice species. Its molecular weight is 338.4 g/mol (C21H22O4). Bioavailability is a key limitation: LA exhibits moderate oral bioavailability due to poor aqueous solubility (lipophilic, logP ~3.5), susceptibility to first-pass metabolism, and rapid hepatic glucuronidation/sulfation, resulting in low plasma concentrations after oral dosing. Nanoparticle encapsulation and lipid-based delivery systems have been shown to improve bioavailability by 2–4 fold in preclinical models. Active concentrations in vitro range from 5–80 μM, though achieving these systemically in vivo requires optimized delivery. No meaningful vitamin, mineral, or macronutrient content is attributed to isolated LA as a purified compound.

Preparation & Dosage

- **Research Extract (In Vitro)**: Dissolved in DMSO to prepare micromolar stock solutions (2–125 μM range); not applicable to human supplementation.
- **In Vivo Rodent Dose**: 20–80 mg/kg body weight administered orally or intraperitoneally in murine models for anti-inflammatory endpoints; human equivalent doses have not been established or validated.
- **Commercial Supplement Forms**: No standardized Licochalcone A supplement exists; it is not currently marketed as a standalone nutritional product. Some broad-spectrum licorice root extracts may contain trace LA, but standardization to LA content is not a regulated or common practice.
- **Traditional Licorice Root Preparation**: Dried G. inflata root decoctions (3–15 g root per day in traditional Chinese medicine) contain unquantified LA alongside glycyrrhizin and other constituents; LA-specific dosing from such preparations is unknown.
- **Standardization Note**: No pharmacopeial or industry standard for LA content in botanical preparations has been established; research-grade LA (≥98% purity by HPLC) is available from chemical suppliers for laboratory use only.
- **Timing and Formulation**: Bioavailability in humans is unknown; lipophilic nature (logP estimated moderate-high) suggests potential for lipid-based formulation enhancement, but this remains speculative without human PK data.

Synergy & Pairings

LA pairs strongly with Quercetin (a flavonoid at 10–50 μM range), as both converge on Bcl-2/Bax apoptotic pathway suppression and share PI3K/Akt inhibition, producing additive-to-synergistic cytotoxicity in cancer cell models while quercetin's inhibition of P-glycoprotein efflux pumps may enhance LA intracellular retention. Curcumin (from Curcuma longa, 10–20 μM) complements LA through overlapping NF-κB suppression and COX-2 inhibition, with curcumin's known ability to upregulate cellular uptake transporters potentially improving LA bioavailability, and both compounds co-targeting Cyclin D1 downregulation for enhanced G1 cell cycle arrest. Piperine (from Piper nigrum, 5–20 mg standardized extract) is a relevant bioavailability enhancer, as it inhibits CYP3A4 and UGT enzymes responsible for LA's rapid Phase I/II metabolism, potentially increasing LA plasma exposure by 30–50% analogous to its established effect on curcumin; additionally, Glycyrrhizin (co-occurring in Glycyrrhiza species, 50–100 mg) may provide complementary anti-inflammatory signaling via HMGB1 suppression without duplicating LA's direct apoptotic mechanism.

Safety & Interactions

Preclinical data indicate that Licochalcone A at 25 μM is non-cytotoxic and viability-enhancing in human adipose-derived stem cells, and in vitro concentrations up to 125 μM and in vivo rodent doses up to 80 mg/kg have not demonstrated overt toxicity in experimental models; however, the absence of human safety data means that a safe human dose cannot be defined. No drug interaction studies have been conducted; given its inhibition of PI3K/AKT/mTOR and CYP enzyme involvement typical of flavonoids, theoretical interactions with anticoagulants, immunosuppressants, and oncology agents warrant caution, though these remain speculative. Contraindications, pregnancy and lactation safety, maximum tolerated dose, and long-term toxicity profiles are entirely unknown due to the complete absence of human clinical or toxicological studies. Consumers should not self-administer isolated Licochalcone A; individuals taking licorice-containing products should be aware that co-occurring glycyrrhizin carries well-documented risks of pseudoaldosteronism, hypertension, and hypokalemia with prolonged use, though this is attributable to glycyrrhizin rather than LA specifically.